October 7, 2015
Federal judge issues permanent injunction against South Dakota’s 2035 Inc
A federal judge in the U.S. District Court for the District of South Dakota yesterday granted the U.S. Food and…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 7, 2015
Lilly Joins the Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, have announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study.
October 7, 2015
Horizon In-licenses Oncology Programme from Servier and Enters Option Agreement
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, has announced that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company .
October 7, 2015
Sanofi: New Analysis on Relapsing Multiple Sclerosis
Sanofi and its subsidiary Genzyme announced have that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis (RMS).
October 7, 2015
AstraZeneca Completes Divestment of Rare Disease Medicine Caprelsa
AstraZeneca has announced the global completion of the divestment of Caprelsa (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company.
October 6, 2015
VIDEO – Take a look at the U.S. government’s response in addressing Ebola in the United States.
Watch a video and take a look at the U.S. government’s response in addressing Ebola in the United States.
October 6, 2015
Recruitment of ARDS patiens for Serendex’s GI HOPE begins in November 2015
The recruitment of patients with ARDS (acute respiratory distress syndrome) for Serendex’s phase II clinical trial – GI HOPE – will begin in November 2015.
October 6, 2015
J&J Announces Completion of Cordis Divestiture to Cardinal Health
Johnson & Johnson has announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments.
October 6, 2015
AmerisourceBergen to Acquire PharMEDium Healthcare Holdings, Inc.
AmerisourceBergen has announced that it has signed a definitive agreement to purchase PharMEDium Healthcare Holdings, Inc., the privately held provider of outsourced compounded sterile preparations (CSPs) to acute care hospitals in the United States, from Clayton, Dubilier & Rice for $2.575 billion in cash, subject to certain adjustments and on a cash-free, debt-free basis.
October 6, 2015
Akers Biosciences Launching BreathScan OxiChek and KetoChek Tests
Akers Biosciences, Inc. a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, has announced that all development specifications have been finalized and production has commenced for its two transformational breath tests designed for the health and wellness industry and consumers.